Dr. Reddy’s says FDA hit its API plant in Hyderabad with Form 483

Dr. Reddy's
Dr. Reddy’s said the FDA has issued one of its API plants a Form 483 following a recent inspection. (Dr. Reddy's)

Indian drugmaker Dr. Reddy’s said that following an inspection, the FDA issued a Form 483 to its API Hyderabad Plant 1, citing four issues.

The company announced the news today in a filing (PDF) to the Bombay Stock Exchange, saying only that the facility located Jinnaram Mandal, Medak District was issued a Form 483 “with four observations which will be addressed comprehensively within stipulated time.”

In a separate and unrelated announcement today, the company said it launched levocetirizine dihydrochloride tablets in the U.S., an OTC antihistamine used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes/nose and sneezing.


Innovative and Flexible Solutions for an End-to-End Patient-Centric, Lean Supply Chain

The trend toward crafting patient-centric clinical trials hold great promise in supporting patients’ willingness and ability to participate in important clinical research. This webinar will explore how recent innovations in forecasting, supply pooling, decentralized processing, labeling, demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric.

The U.S. regulatory agency has put Dr. Reddy’s under intense scrutiny in the past few years. Last spring, the Indian drugmaker said an inspection by the FDA of a formulations plant in Bachupally in Hyderabad resulted in a Form 483 with 11 observations.

In November, German regulators signed off on a corrective and preventive action plan (CAPA) for one of Dr. Reddy’s formulation production at another of its facilities in India, allowing the company to market drugs manufactured at the site for the European Union.

Being under the regulatory magnifying glass has had a fiscal impact on the company. Last May, the company reported that revenues in North America were off 16% to 63.6 billion rupees ($993 million). At the time, Dr. Reddy’s said the slump was due to increased competition to a key drug in the market but also acknowledged that the FDA's problems with its manufacturing had again taken a toll.


Suggested Articles

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Catalent is buying a site in Italy from Bristol-Myers Squibb that handles biologics along with old-school solid dose production.

Here is some more manufacturing news from the week.